MX2016004928A - Secuencias de anticuerpos con reaccion cruzada para staphylococcus aureus. - Google Patents
Secuencias de anticuerpos con reaccion cruzada para staphylococcus aureus.Info
- Publication number
- MX2016004928A MX2016004928A MX2016004928A MX2016004928A MX2016004928A MX 2016004928 A MX2016004928 A MX 2016004928A MX 2016004928 A MX2016004928 A MX 2016004928A MX 2016004928 A MX2016004928 A MX 2016004928A MX 2016004928 A MX2016004928 A MX 2016004928A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- parent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Abstract
La invención se refiere a un anticuerpo con neutralización cruzada que comprende por lo menos un sitio de unión poliespecífico que se une a la toxina alfa (Hla) y por lo menos una de las toxinas de dos componentes de Staphylococcus aureus, y el anticuerpo comprende por lo menos tres regiones determinantes de complementariedad (CDR1 a CDR3) de la región variable de cadenas pesadas de anticuerpos (VH), en donde A) el anticuerpo comprende a) una CDR1 que comprende o que consiste en la secuencia de aminoácidos YSISSGMGWG (SEQ ID 1); y b) una CDR2 que comprende o que consiste en la secuencia de aminoácidos SIDQRGSTYYNPSLKS (SEQ ID 2); y c) una CDR3 que comprende o que consiste en la secuencia de aminoácidos ARDAGHGVDMDV (SEQ ID 3); o B) el anticuerpo comprende por lo menos una variante de CDR funcionalmente activa de a) la CDR1 de origen que consiste en la secuencia de aminoácidos de la SEQ ID 1; o b) la CDR2 de origen que consiste en la secuencia de aminoácidos de la SEQ ID 2; o c) la CDR3 de origen que consiste en la secuencia de aminoácidos de la SEQ ID 3; en donde la variante de CDR funcionalmente activa comprende por lo menos una mutación puntual en la secuencia CDR de origen, y comprende o consiste en la secuencia de aminoácidos que tiene por lo menos 60% de identidad de secuencias con la secuencia CDR de origen. Además se refiere a tal anticuerpo con neutralización cruzada que es un anticuerpo variante funcionalmente activo de un anticuerpo de origen que comprende un sitio de unión poliespecífico de la secuencia de aminoácidos de VH de la SEQ ID 20, y la secuencia de aminoácidos de VL de la SEQ ID 39, y el anticuerpo variante funcionalmente activo comprende por lo menos una mutación puntual en cualquiera de las regiones marco (FR) o dominios constantes, o regiones determinantes de la complementariedad (CDR1 a CDR6) en cualquiera de las SEQ ID 20 o SEQ 39, y tiene una afinidad para unirse a cada una de las toxinas con una Kd de menos de 10-8 M, preferiblemente menos de 10-9 M.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13189095 | 2013-10-17 | ||
| PCT/EP2014/072316 WO2015055814A1 (en) | 2013-10-17 | 2014-10-17 | Cross-reactive staphylococcus aureus antibody sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016004928A true MX2016004928A (es) | 2016-07-11 |
Family
ID=49356347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004928A MX2016004928A (es) | 2013-10-17 | 2014-10-17 | Secuencias de anticuerpos con reaccion cruzada para staphylococcus aureus. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160244511A1 (es) |
| EP (1) | EP3057989A1 (es) |
| JP (1) | JP6473746B2 (es) |
| KR (1) | KR20160067977A (es) |
| CN (1) | CN105873946A (es) |
| AU (1) | AU2014336111A1 (es) |
| BR (1) | BR112016008275A2 (es) |
| CA (1) | CA2925071A1 (es) |
| IL (1) | IL244936A0 (es) |
| MX (1) | MX2016004928A (es) |
| RU (1) | RU2016119052A3 (es) |
| WO (1) | WO2015055814A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160244511A1 (en) * | 2013-10-17 | 2016-08-25 | Arsanis Biosciences Gmbh | Cross-reactive staphylococcus aureus antibody sequences |
| EP3283514A1 (en) * | 2015-04-17 | 2018-02-21 | ARSANIS Biosciences GmbH | Anti-staphylococcus aureus antibody combination preparation |
| TW202311284A (zh) * | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| WO2018165089A1 (en) * | 2017-03-06 | 2018-09-13 | Vanderbilt University | Human monoclonal antibodies to staphylococcus aureus lukab toxin |
| CA3115765A1 (en) * | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Antibodies directed against staphylococcus aureus leukotoxins |
| BR112021006622A2 (pt) | 2018-10-09 | 2021-07-20 | Medimmune, Llc | combinações de anticorpos anti-staphylococcus aureus |
| CN109400704B (zh) * | 2018-11-14 | 2020-07-21 | 珠海泰诺麦博生物技术有限公司 | 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用 |
| RU2705415C1 (ru) * | 2019-01-10 | 2019-11-07 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Способ диагностики стафилококковой абдоминальной хирургической инфекции |
| CN114106183B (zh) * | 2019-01-15 | 2023-06-23 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
| CN114369165B (zh) * | 2021-12-31 | 2023-04-18 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌毒力因子GapC的单链抗体、制备方法及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| JP2009539979A (ja) * | 2006-06-12 | 2009-11-19 | ナビ バイオファーマシューティカルズ | ブドウ球菌感染症を治療および予防するための、α毒素の使用 |
| US20180221466A9 (en) * | 2006-06-12 | 2018-08-09 | Glaxosmithkline Biologicals S.A. | Use of alpha-toxin for treating and preventing staphylococcus infections |
| JP5754135B2 (ja) | 2007-03-26 | 2015-07-29 | アジェナス インコーポレイテッド | 関心対象のタンパク質の細胞表面ディスプレイ、スクリーニング、および産生 |
| BRPI0816785A2 (pt) | 2007-09-14 | 2017-05-02 | Adimab Inc | bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP3187877A1 (en) | 2009-09-25 | 2017-07-05 | XOMA Technology Ltd. | Screening methods |
| US8431687B2 (en) * | 2010-05-05 | 2013-04-30 | New York University | Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof |
| KR102159272B1 (ko) | 2010-07-16 | 2020-09-24 | 아디맵 엘엘씨 | 항체 라이브러리 |
| WO2012109285A2 (en) * | 2011-02-08 | 2012-08-16 | Medimmune, Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| ES2684088T3 (es) * | 2011-06-19 | 2018-10-01 | New York University | Métodos de tratamiento y prevención de infecciones por staphylococcus aureus y afecciones asociadas |
| JP6317670B2 (ja) * | 2011-08-15 | 2018-04-25 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ブドウ球菌プロテインａに対する抗体に関連した組成物および方法 |
| LT2785368T (lt) * | 2011-12-02 | 2019-06-10 | Integrated Biotherapeutics, Inc. | Imunogeninė kompozicija, apimanti polipeptidus, kilusius iš pantono-valentino leukocidino (pvl) |
| ES2546105T3 (es) * | 2012-04-17 | 2015-09-18 | Arsanis Biosciences Gmbh | Anticuerpo de reacción cruzada contra Staphylococcus aureus |
| AU2014270598B2 (en) * | 2013-05-21 | 2018-09-20 | Arsanis Biosciences Gmbh | Generation of highly potent antibodies neutralizing the LukGH (LukAB) toxin of Staphylococcus aureus |
| US20160244511A1 (en) * | 2013-10-17 | 2016-08-25 | Arsanis Biosciences Gmbh | Cross-reactive staphylococcus aureus antibody sequences |
| JP2017505758A (ja) * | 2013-12-19 | 2017-02-23 | アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 黄色ブドウ球菌のｌｕｋｇｈ（ｌｕｋａｂ）毒素に対する抗体及び抗体配列 |
| EP3283514A1 (en) * | 2015-04-17 | 2018-02-21 | ARSANIS Biosciences GmbH | Anti-staphylococcus aureus antibody combination preparation |
-
2014
- 2014-10-17 US US15/029,944 patent/US20160244511A1/en not_active Abandoned
- 2014-10-17 EP EP14793035.8A patent/EP3057989A1/en not_active Withdrawn
- 2014-10-17 CA CA2925071A patent/CA2925071A1/en not_active Abandoned
- 2014-10-17 AU AU2014336111A patent/AU2014336111A1/en not_active Abandoned
- 2014-10-17 JP JP2016523961A patent/JP6473746B2/ja not_active Expired - Fee Related
- 2014-10-17 BR BR112016008275A patent/BR112016008275A2/pt not_active Application Discontinuation
- 2014-10-17 KR KR1020167012583A patent/KR20160067977A/ko not_active Application Discontinuation
- 2014-10-17 RU RU2016119052A patent/RU2016119052A3/ru not_active Application Discontinuation
- 2014-10-17 WO PCT/EP2014/072316 patent/WO2015055814A1/en active Application Filing
- 2014-10-17 CN CN201480069544.1A patent/CN105873946A/zh active Pending
- 2014-10-17 MX MX2016004928A patent/MX2016004928A/es unknown
-
2016
- 2016-04-05 IL IL244936A patent/IL244936A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016119052A3 (en) | 2018-09-10 |
| BR112016008275A2 (pt) | 2017-10-03 |
| JP2016535985A (ja) | 2016-11-24 |
| AU2014336111A1 (en) | 2016-04-14 |
| RU2016119052A (ru) | 2017-11-22 |
| US20160244511A1 (en) | 2016-08-25 |
| IL244936A0 (en) | 2016-05-31 |
| JP6473746B2 (ja) | 2019-02-20 |
| EP3057989A1 (en) | 2016-08-24 |
| WO2015055814A1 (en) | 2015-04-23 |
| CN105873946A (zh) | 2016-08-17 |
| CA2925071A1 (en) | 2015-04-23 |
| KR20160067977A (ko) | 2016-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004928A (es) | Secuencias de anticuerpos con reaccion cruzada para staphylococcus aureus. | |
| MX2020010382A (es) | Anticuerpos biespecificos para pd1 y tim3. | |
| PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| NZ739028A (en) | Humanized or chimeric cd3 antibodies | |
| MY186351A (en) | Multispecific antibodies | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| NZ626269A (en) | Anti-phf-tau antibodies and their uses | |
| EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
| NZ726258A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| WO2012109285A3 (en) | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use | |
| EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| PE20210377A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| BR112014005644A2 (pt) | anticorpo anti-alfabetatcr | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| MX2016008794A (es) | Secuencias de anticuerpos especificos para e. coli. | |
| RU2014100111A (ru) | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| MX2016007212A (es) | Anticuerpos dirigidos contra la toxina lukgh (lukab) de staphylococcus aureus y secuencias de anticuerpos. | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
| WO2016112078A3 (en) | Anti-phf-tau antibodies and their uses |